(Corrects to say Zejula and Jemperli as a maintenance therapy in first paragraph, not maintenance therapy Zejula)
(Reuters) – GSK said on Monday its cancer drug Jemperli along with chemotherapy and followed by Zejula and Jemperli as a maintenance therapy met the primary goal of progression-free survival in patients with advanced or recurrent endometrial cancer in a late-stage trial.
The British company said the trial met the primary goal with a “statistically significant and clinically meaningful” benefit observed in both the overall patient population and in a subpopulation of patients with certain types of tumours.
(This story has been corrected to say ‘Zejula and Jemperli as a maintenance therapy’ instead of ‘maintenance therapy Zejula’ in paragraph 1)
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Sonia Cheema)
